TP53 and acute myeloid leukemia: Preliminary Phase 2 results in patients with acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome with mutated p53 show no responses of cancer to therapy to date (Jonas et al., 2022).